Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardiology and Angiology 2022 August;70(4) > Minerva Cardiology and Angiology 2022 August;70(4):431-8

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Cardiology and Angiology 2022 August;70(4):431-8

DOI: 10.23736/S2724-5683.21.05802-6

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients

Tuğba K. ÖZ 1, 2 , Mahmoud ABDELNABİ 3, 4, Corrado FIORE 5, Abdallah ALMAGHRABY 6, Deniz CİHAN 7, Nigar BABAZADE 8, Syed HASEEB RAZA NAQVİ 9, Bahadır OMAR 10, Bahadır DAĞDEVİREN 7

1 Department of Cardiology, Faculty of Medicine, Istinye University, Istanbul, Turkey; 2 Department of Cardiology, Liv Hospital Ulus, Istanbul, Turkey; 3 Clinical and Experimental Internal Medicine Department, Medical Research Institute, Alexandria University, Alexandria, Egypt; 4 Department of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX, USA; 5 Department of Cardiology, Citta di Lecce Hospital GVM Care and Research, Lecce, Italy; 6 Department of Cardiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt; 7 Department of Cardiology, Faculty of Medicine, Bahcesehir University, Istanbul, Turkey; 8 Department of Cardiology, Baku Health Clinic, Baku, Azerbaijan; 9 Department of Cardiology, National Institute of Cardiovascular Diseases, Sindh, Pakistan; 10 Department of Cardiology, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey



BACKGROUND: Three-dimensional (3D) echocardiography and 3D strain parameters have been used for a comprehensive quantitative assessment of left ventricular (LV) myocardial dynamics. So far, there are no data on sacubitril/valsartan effects on cardiac functions and LV reverse remodeling using 3D echocardiography. This study aimed to evaluate the effects of sacubitril/valsartan on the LV functions using two-dimensional (2D) echocardiography, 3D echocardiography, and the 3D strain parameters.
METHODS: A single-center prospective cohort study which included 100 heart failure with reduced ejection fraction (HFrEF) patients with guidelines-approved indications for sacubitril/valsartan treatment. Patients received a short course (3-month) of sacubitril/valsartan. 3-month follow-up 2D, 3D echocardiographic parameters, and 3D strain were compared to baseline parameters.
RESULTS: The results of the study revealed a significant improvement in left ventricular dynamic functions at 3-month follow-up with an improvement in left ventricular systolic function (mean left ventricular ejection fraction (LVEF) increased from 27.65±4.98% to 32.89±6.03%, P<0.001). Comparison of HFrEF patients with ischemic and non-ischemic etiologies showed that echocardiographic parameters significantly improved in both groups after 3 months of sacubitril/valsartan treatment. There was no statistically significant difference between both groups regarding echocardiographic parameters at baseline and 3-month follow-up.
CONCLUSIONS: In a single-center prospective observational cohort study evaluating the effects of short-term (3-month course) sacubitril/valsartan treatment on LV dynamics assessed by 3D echocardiography and 3D strain, sacubitril/valsartan was associated with a significant improvement of LV systolic functions and reverse remodeling effects in both ischemic and non-ischemic HFrEF patients.


KEY WORDS: Heart Failure, systolic; Sacubitril; Valsartan; Echocardiography, three-dimensional; Ventricular remodeling

top of page